Soleno Therapeutics, Inc. Email Format

Pharmaceutical ManufacturingCalifornia, United States51-200 Employees

Soleno Therapeutics, Inc. is a public pharmaceutical manufacturing company headquartered in Redwood City, California at 100 Marine Parkway, Suite 400, 94065. The company focuses on therapies for Prader-Willi syndrome and other rare diseases, including a hyperphagia treatment that received FDA approval in March 2025, described as the first and only therapy for hyperphagia in Prader-Willi syndrome. It employs between 51 and 200 people. Soleno Therapeutics is listed on NASDAQ under ticker SLNO. In 2026, the company faced multiple securities-related lawsuits and investigations pertaining to its drug launch and corporate disclosures. Financial disclosures indicate revenue in the range of $100 million to $250 million and total funding around $200 million.

Sign up for free to view info

Company overview Employee directory